Skip to content
TrialScanner

NCT03752099

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Phase 1/Phase 2TerminatedVERULead

Registry record

Lead sponsor
Veru Inc.
Conditions
Metastatic Castration Resistant Prostate Cancer
Primary completion
Mar 15, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03752099 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03752099: To Evaluate Safety and... | TrialScanner